Veeva

Name: Veeva
Brand: Veeva

Leader

The Industry Cloud for Life Sciences

Est 2007|Valuation $52.2B|Raised $201.4M|123 Ref Customers

LinkedIn 320K|Web traffic 568K|FTEs 7,928|HQ Pleasanton, California, US

MarketsQuality Assurance ERP

Published Oct 22, 2026

01Common complaints

Consider alternatives or delay adoption when: 1. The organization is a small or early-stage biotech with limited budget and needs a low-cost, lightweight solution. 2. The primary requirement is flexible, ad-hoc reporting or BI without willingness to invest in specialist configuration. 3. There is no capacity or willingness to maintain internal administrators and the organization does not want ongoing dependence on paid partner services. 4. The primary purchase is commercial CRM and transparent per-user pricing is required; competitors publish list pricing that may be preferable for straightforward buying decisions. 5. The organization is highly sensitive to workflow overhead and prefers minimal, ad-hoc process steps over structured, multi-step controlled processes.

Deal disqualifiers (poor fit)

Very small teams seeking low-cost, lightweight tools
Organizations requiring extensive bespoke processes that conflict with structured Vault models
Teams that require large amounts of ad-hoc, self-service reporting without specialist configuration

Issues reported by users

Reporting flexibility and ease-of-use are commonly cited areas for improvement.
Training administration and documented admin enablement can be unclear.
Document formatting and import processes can cause friction for content teams.
Performance concerns have been reported for very large datasets.

Vendor roadmap and forward-looking items (publicly described)

The vendor has announced AI agent capabilities with staged availability across commercial and R&D/quality applications during late 2025 and 2026 in investor materials and release notes. Procurement teams should confirm which AI features are included with specific products and contracts, and whether vendor statements about inclusion through specified future dates are contractually guaranteed.

Where it struggles (from reviewer commentary)

Administrative training and enablement for new admins
Reporting and custom analytics without specialist effort
Performance and latency at scale for very large datasets

02Why they buy

Unique selling points supported by reviewer evidence

Collaborative review and approval workflows (notably in PromoMats) are reported by reviewers to consolidate comments and manage approvals for promotional and regulated content.
Domain-specific compliance workflows (quality, regulatory, clinical) are frequently cited as a principal reason organizations adopt Veeva applications.

Vendor claims that need validation

Vendor marketing statements that imply universally superior outcomes or cost-free long-term features should be validated in contract terms. For example, vendor statements about AI features being included at no cost through 2030 should be confirmed with contractual detail (scope, usage limits, applicability, and future pricing contingencies).

03Field reports

Review platform summary signals

G2 vendor presence: well rated on G2.
Veeva Vault on G2: well rated on G2.
Veeva Vault on Capterra: very highly rated on Capterra.
Veeva CRM on Capterra: very highly rated on Capterra.

Reviewer comments — positive (examples, paraphrased)

Reviewers praise consistent core features across modules and note that integrations and customization options enable added functionality.
Users highlight collaboration and approval-tracking features, stating that consolidated review and commenting support streamlines reviews and approvals.
Some feedback points to effective surfacing of data quality issues, helping teams identify errors promptly.

Reviewer comments — negative / critical (examples, paraphrased)

- Document formatting challenges have been reported when importing content into Vault. - Some users describe gaps in structured administrative training, noting a reliance on on-the-job learning for admins. - Professional services and vendor-provided assistance are frequently cited as a significant cost, and full implementations often involve paid services. - Reporting capabilities are criticized for limited out-of-the-box flexibility and difficulty constructing complex reports without specialist configuration. - Performance and latency issues are reported by some users when working with very large datasets.

Why customers choose Veeva (themes)

Recurring selection drivers from reviews and product positioning include:

Life-sciences-oriented workflows and templates tailored to regulated processes
Built-in auditability and features supporting compliance needs
Platform consistency across applications (shared Vault platform)
Consolidated review and approval workflows, particularly for promotional materials and controlled documents

Why some customers churn or do not buy (themes)

Perceived high cost relative to smaller-company budgets
Complexity and multi-step workflows that require investment in administrative skills
Reporting limitations without specialist configuration
Reported performance issues on large datasets
Commercial competition: market reporting indicates some top-tier CRM accounts have chosen alternatives such as Salesforce

What was found in the sources reviewed

The materials reviewed for this run included investor and press releases, trust and security overviews, partner ecosystem pages, and review-platform commentary. Detailed case studies with independently verified, quantified metrics (such as percent cycle-time reduction or days saved) were not identified in the reviewed set.

Critical evaluation approach (what to request)

To evaluate case study claims rigorously, request from the vendor or reference customers: - Baseline and post-implementation metrics with defined measurement methodologies - Attribution details (what changes were made besides software) - Sample size and time period for reported improvements - Whether results were vendor-calculated or independently verified Note: Company releases and investor materials often report customer additions and product adoption metrics; these are company statements and should be corroborated when evaluating expected outcomes.

04Best fit

Best-fit organizations

Company size: mid-market to large enterprise life sciences organizations with budgets and governance for multi-year regulated platforms. Smaller biotechs may adopt, but cost can be a barrier.
Industries: pharmaceutical, biotech, medtech, CROs and specialized service providers.

Roles and personas

Decision makers: CIO/CTO, VP Quality, VP Regulatory, Head of Clinical Operations, Commercial Operations leadership.
Key users: quality managers, regulatory operations, clinical trial managers, field sales/medical teams (for CRM), and platform administrators.
IT stakeholders: validation/CSV leads, platform admins, and integration architects.

Key pain points addressed

Audit-ready processes and controlled document lifecycles
Cross-functional collaboration within regulated workflows
Reducing fragmentation across point solutions in regulated operations

Qualification criteria (good fit)

Need for validated, compliant workflows
Willingness to adopt vendor-provided workflow templates and structured models
Ability to fund implementation partners and an internal admin team

05The pitch

What the product does (objective value proposition)

Veeva Systems provides industry-specific cloud software for life sciences organizations across: - Commercial (CRM, omnichannel engagement, MDM, analytics) - R&D (clinical operations, clinical data, regulatory, safety) - Quality (QMS/eQMS, document control, training, deviations/CAPA) The primary offering is the Veeva Vault Platform: a standardized but configurable platform designed for regulated GxP workflows. The platform combines content and structured data, supports auditability and electronic signatures, and includes validated change control patterns intended to support regulated processes.

Target market and positioning

Primary buyers: pharmaceutical, biotech, medtech, and related service providers (CROs, partners).
Positioning: marketed as an industry-specific cloud for life sciences, emphasizing standardization and compliance-oriented workflows.
Enterprise footprint: the product has notable adoption among large biopharma; market commentary notes competitive dynamics in CRM versus Salesforce as Vault CRM adoption grows.

Get a comprehensive analysis of Veeva including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Oct 22, 2026

01Common complaints

Consider alternatives or delay adoption when:

The organization is a small or early-stage biotech with limited budget and needs a low-cost, lightweight solution.
The primary requirement is flexible, ad-hoc reporting or BI without willingness to invest in specialist configuration.
There is no capacity or willingness to maintain internal administrators and the organization does not want ongoing dependence on paid partner services.
The primary purchase is commercial CRM and transparent per-user pricing is required; competitors publish list pricing that may be preferable for straightforward buying decisions.
The organization is highly sensitive to workflow overhead and prefers minimal, ad-hoc process steps over structured, multi-step controlled processes.

Deal disqualifiers (poor fit)

Very small teams seeking low-cost, lightweight tools
Organizations requiring extensive bespoke processes that conflict with structured Vault models
Teams that require large amounts of ad-hoc, self-service reporting without specialist configuration

Issues reported by users

Reporting flexibility and ease-of-use are commonly cited areas for improvement.
Training administration and documented admin enablement can be unclear.
Document formatting and import processes can cause friction for content teams.
Performance concerns have been reported for very large datasets.

Vendor roadmap and forward-looking items (publicly described)

The vendor has announced AI agent capabilities with staged availability across commercial and R&D/quality applications during late 2025 and 2026 in investor materials and release notes. Procurement teams should confirm which AI features are included with specific products and contracts, and whether vendor statements about inclusion through specified future dates are contractually guaranteed.

Where it struggles (from reviewer commentary)

Administrative training and enablement for new admins
Reporting and custom analytics without specialist effort
Performance and latency at scale for very large datasets

02Why they buy

Unique selling points supported by reviewer evidence

Collaborative review and approval workflows (notably in PromoMats) are reported by reviewers to consolidate comments and manage approvals for promotional and regulated content.
Domain-specific compliance workflows (quality, regulatory, clinical) are frequently cited as a principal reason organizations adopt Veeva applications.

Vendor claims that need validation

Vendor marketing statements that imply universally superior outcomes or cost-free long-term features should be validated in contract terms. For example, vendor statements about AI features being included at no cost through 2030 should be confirmed with contractual detail (scope, usage limits, applicability, and future pricing contingencies).

03Field reports

Review platform summary signals

G2 vendor presence: well rated on G2.
Veeva Vault on G2: well rated on G2.
Veeva Vault on Capterra: very highly rated on Capterra.
Veeva CRM on Capterra: very highly rated on Capterra.

Reviewer comments — positive (examples, paraphrased)

Reviewers praise consistent core features across modules and note that integrations and customization options enable added functionality.
Users highlight collaboration and approval-tracking features, stating that consolidated review and commenting support streamlines reviews and approvals.
Some feedback points to effective surfacing of data quality issues, helping teams identify errors promptly.

Reviewer comments — negative / critical (examples, paraphrased)

Document formatting challenges have been reported when importing content into Vault.
Some users describe gaps in structured administrative training, noting a reliance on on-the-job learning for admins.
Professional services and vendor-provided assistance are frequently cited as a significant cost, and full implementations often involve paid services.
Reporting capabilities are criticized for limited out-of-the-box flexibility and difficulty constructing complex reports without specialist configuration.
Performance and latency issues are reported by some users when working with very large datasets.

Why customers choose Veeva (themes)

Recurring selection drivers from reviews and product positioning include:

Life-sciences-oriented workflows and templates tailored to regulated processes
Built-in auditability and features supporting compliance needs
Platform consistency across applications (shared Vault platform)
Consolidated review and approval workflows, particularly for promotional materials and controlled documents

Why some customers churn or do not buy (themes)

Perceived high cost relative to smaller-company budgets
Complexity and multi-step workflows that require investment in administrative skills
Reporting limitations without specialist configuration
Reported performance issues on large datasets
Commercial competition: market reporting indicates some top-tier CRM accounts have chosen alternatives such as Salesforce

What was found in the sources reviewed

Critical evaluation approach (what to request)

To evaluate case study claims rigorously, request from the vendor or reference customers:

Baseline and post-implementation metrics with defined measurement methodologies
Attribution details (what changes were made besides software)
Sample size and time period for reported improvements
Whether results were vendor-calculated or independently verified

Note: Company releases and investor materials often report customer additions and product adoption metrics; these are company statements and should be corroborated when evaluating expected outcomes.

04Best fit

Best-fit organizations

Company size: mid-market to large enterprise life sciences organizations with budgets and governance for multi-year regulated platforms. Smaller biotechs may adopt, but cost can be a barrier.
Industries: pharmaceutical, biotech, medtech, CROs and specialized service providers.

Roles and personas

Decision makers: CIO/CTO, VP Quality, VP Regulatory, Head of Clinical Operations, Commercial Operations leadership.
Key users: quality managers, regulatory operations, clinical trial managers, field sales/medical teams (for CRM), and platform administrators.
IT stakeholders: validation/CSV leads, platform admins, and integration architects.

Key pain points addressed

Audit-ready processes and controlled document lifecycles
Cross-functional collaboration within regulated workflows
Reducing fragmentation across point solutions in regulated operations

Qualification criteria (good fit)

Need for validated, compliant workflows
Willingness to adopt vendor-provided workflow templates and structured models
Ability to fund implementation partners and an internal admin team

05The pitch

What the product does (objective value proposition)

Veeva Systems provides industry-specific cloud software for life sciences organizations across:

Commercial (CRM, omnichannel engagement, MDM, analytics)
R&D (clinical operations, clinical data, regulatory, safety)
Quality (QMS/eQMS, document control, training, deviations/CAPA)

The primary offering is the Veeva Vault Platform: a standardized but configurable platform designed for regulated GxP workflows. The platform combines content and structured data, supports auditability and electronic signatures, and includes validated change control patterns intended to support regulated processes.

Target market and positioning

Primary buyers: pharmaceutical, biotech, medtech, and related service providers (CROs, partners).
Positioning: marketed as an industry-specific cloud for life sciences, emphasizing standardization and compliance-oriented workflows.
Enterprise footprint: the product has notable adoption among large biopharma; market commentary notes competitive dynamics in CRM versus Salesforce as Vault CRM adoption grows.

Get a comprehensive analysis of Veeva including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →